In Vitro Immunogenicity Evaluation Services for Veterinary (Pet) Antibody

Are you facing challenges with unpredicted immunogenicity, loss of efficacy, or potential adverse events for your therapeutic antibodies in companion animals? Creative Biolabs' in vitro immunogenicity evaluation service helps you de-risk and select the most promising antibody candidates early in development. By using advanced, species-specific cellular assays with primary immune cells from canine and feline donors, we provide critical data to guide the engineering and selection of safer, more effective veterinary biologics.

Antibody Immunogenicity Evaluation Services

Developing antibody-based therapies for companion animals marks a transformative step forward in veterinary healthcare. However, a critical hurdle is immunogenicity, the potential for a biologic to induce an unwanted immune response in the treated animal. Such a response can neutralize the therapeutic effect of the antibody, alter its pharmacokinetic profile, or, in some cases, lead to serious adverse events. Creative Biolabs' in vitro immunogenicity evaluation service is designed to proactively address this challenge. We provide you with a robust, early-stage assessment of your antibody candidate's immunogenic potential, specifically within the target canine or feline immune system. We deliver a detailed immunogenicity risk assessment, enabling early-stage candidate comparison, supporting deimmunization strategies, and guiding informed decisions before investing in long-term in vivo studies. By identifying and mitigating immunogenicity risk at the discovery stage, we help you focus your resources on candidates with the highest probability of clinical success.

Discover How We Can Help - Request a Consultation

T Cell Activation Evaluation
A key initiating event in the adaptive immune response against a therapeutic protein is the activation of T helper cells. Our service directly measures this critical step. Using peripheral blood mononuclear cells (PBMCs) isolated from healthy, treatment-naïve canine or feline donors, we assess T cell responses upon exposure to your antibody candidate. The detailed evaluation pinpoints the potential for your antibody to stimulate the cellular machinery responsible for a sustained antibody response.
Cytokine Release Evaluation
Upon activation, T cells and other immune cells release a cascade of signaling molecules called cytokines. The specific profile of these cytokines can reveal the nature and intensity of the immune response. An inappropriate or excessive cytokine release can be linked to both immunogenicity and other acute adverse reactions. Our platform features ultrasensitive assays to accurately measure cytokine secretion in response to therapeutic antibody candidates.

Antibody IVCIA Assays. (Joubert, et al., 2016) (OA Literature) Fig 1 Antibody In Vitro Comparative Immunogenicity Assessment (IVCIA) Assays.^1,2

Workflow

Our in vitro immunogenicity evaluation service is designed to assess the potential of veterinary antibody candidates to elicit immune responses in target species. This data is critical for minimizing adverse reactions and optimizing therapeutic design before in vivo studies.

Fig 1. Pet Antibody In Vitro Immunogenicity Evaluation Service Workflow. (Creative Biolabs Original)

Project Consultation & Assay Design	We begin by gathering details on your antibody candidate (species, isotype, sequence format) and therapeutic context. Based on your target species, we recommend a customized panel of in vitro assays, such as dendritic cell activation, T cell proliferation, or cytokine release assays.
PBMC or Immune Cell Sourcing	We source or use client-supplied peripheral blood mononuclear cells (PBMCs) or immune cells from the relevant veterinary species. Consistency and biological relevance are ensured through rigorous screening and documentation of healthy donor samples.
In Vitro Assay Execution	Antigen Presentation Assay We assess dendritic cell activation and antigen uptake to characterize innate immune responses following antibody treatment. T Cell Proliferation Assay We measure T cell responses to antibody-treated APCs using CFSE dilution or thymidine incorporation. Cytokine Release We quantify pro-inflammatory cytokines (e.g., IL-2, IFN-γ, TNF-α) via ELISA or multiplex platforms.
Data Analysis & Interpretation	Quantitative and qualitative immune response data are collected via flow cytometry, imaging, or plate-based assays. We analyze results for immunogenicity risk ranking, comparing candidate antibodies or formats. A comprehensive report is delivered, including methodology, raw and processed data, immunogenicity profiles, and risk assessment insights. Optional recommendations for sequence optimization or Fc engineering are available upon request.

Why Choose Us?

Unparalleled Species Specificity
Our assays are not repurposed from human models. We utilize authenticated PBMCs from diverse canine and feline donor pools, providing the most clinically relevant in vitro system to predict immunogenicity in your target population.
Multi-Parameter Analysis
We go beyond simple proliferation assays. By integrating T cell activation marker analysis with multiplex cytokine profiling, we deliver a multi-faceted view of the immune response, offering deeper mechanistic insights.
Proven Track Record and Reliability
Our robust, validated assay platforms deliver reproducible and high-quality data that our clients rely on to de-risk their pipelines and guide their development strategies.

FAQs

1. What if my antibody candidate shows a high immunogenicity signal in your assay?

This is valuable information, not a dead end! A high-risk result allows you to make an early, informed decision to either terminate the candidate, select a backup, or use the data to guide protein engineering efforts to "deimmunize" the molecule by removing the problematic T cell epitopes. We are happy to consult on potential next steps.

Related Services

To fully characterize your veterinary antibody, Creative Biolabs offers a suite of complementary in vitro evaluation services.

In Vitro Cell Binding Evaluation

Quantify the binding affinity and kinetics of your antibody to its target on canine or feline cells.

In Vitro Specificity & Cross-Reactivity Evaluation

Our tissue cross-reactivity studies help confirm binding specificity and eliminate the risk of off-target effects.

In Vitro Biological Functionality Evaluation

Confirm the intended biological activity of your antibody, such as blocking a receptor or inducing antibody-dependent cell-mediated cytotoxicity (ADCC).

In Vitro PK/PD Evaluation

Conduct early, in vitro studies to model the pharmacokinetic and pharmacodynamic properties of your therapeutic candidate.

In Vivo Immunogenicity Evaluation

We provide comprehensive in vivo immunogenicity evaluation services to assess the immune response elicited by veterinary therapeutic antibody candidates in relevant animal models, ensuring safety and efficacy prior to clinical application.

Partner with Creative Biolabs

Creative Biolabs is committed to driving innovation in veterinary therapeutics through high-quality, data-driven preclinical evaluation services. Our in vitro immunogenicity evaluation service provides the critical data you need to select and engineer safer, more effective antibody therapeutics for the pets that need them most.

Contact our team to learn more about our customized solutions for your pet therapeutic antibody in vitro immunogenicity assays.

Contact Our Team for More Information and to Discuss Your Project.

References

Joubert, Marisa K et al. "Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics." PloS one vol. 11,8 e0159328. 5 Aug. 2016, https://doi.org/10.1371/journal.pone.0159328
Distributed under Open Access license CC BY 4.0, without modification.

Services